4,901 trials
Chronic Interstitial Cystitis
Primary: Percentage of Participants by Change From Baseline in Appearance of Hunner's Lesions at Day 14 — 0.0; 85.7; 14.3; 0.0 percentage of participants
Dose Finding Study
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 0; 50.0; 0 percentage of participants
Malignant Melanoma
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC [0-inf]) in the Fasted and Fed States — 115; 351 micrograms*hour per milliliter (µg*h/mL)
Healthy
Primary: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline — 0; 0; 0; 0 participants
Prostate Cancer
Primary: The Primary Endpoint is the Proportion of Patients Maintained on Mitotane After 12 Consecutive Weeks of Therapy. A Positive Outcome Would be Seeing 50% or More Patients…
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration) — 2830…
Healthy
Primary: Percentage of Participants With Drug Related Adverse Events — 0.0; 0.0; 0.0; 0.0 Percentage of participants
Healthy
Primary: Number (%) of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 0.0 Percentage of Participants
Lymphocytic Leukemia, Chronic
Primary: Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab — 1600 mg
Colorectal and Ovarian Cancer Patients With Liver Metastases
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) — 1; 1; 0; 2 Subjects
Polysomnography
Primary: Latency to Persistent Sleep (LPS) Following Single Doses of MK-1064 and Placebo — 4.27; 3.68; 2.67; 17.93 minutes
Solid Cancers
Primary: Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State — -8.4 milliseconds (msec)
Heartburn
Primary: Area Under the Concentration-time Curve From 0 to Infinity (AUC 0-∞) Following Single Dose Administration of Famotidine CT Without Water and Famotidine FCT With Water…
Solid Cancers
Primary: Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady-State for Both Total and Unbound GDC-0449 — 24; 72; 15; 74 hours
Malignant Melanoma
Primary: Plasma RO5185426 Trough Concentrations on Days 15,16, and 17 — 61.1; 67.7; 61.5 micrograms per milliliter